Literature DB >> 23305975

Statistical methods and tool for cut point analysis in immunogenicity assays.

Lanju Zhang1, Jianchun Jason Zhang, Robert J Kubiak, Harry Yang.   

Abstract

Administration of biopharmaceutical products can generate immune response that may severely impact the safety or efficacy of the products. Immunogenicity evaluation, required by regulatory agencies, relies on well developed and validated assays. Key to such assay development is the determination of a cut point during assay validation. Although many methods have been suggested in literature, they are either too complicated to be of practical use by scientists without ready assistance of statisticians or lacking statistical justification. In this paper, we discuss statistical considerations on cut point analysis in immunogenicity assay validation, with a focus on data normalization, outlier detection, and cut point calculation. Also provided is a statistical procedure for cut point determination which maintains a good balance between statistical rigor and implementation simplicity. To facilitate the implementation of the procedure, a software tool is developed, using R language, to automate the proposed process. Taken together the proposed approach renders scientists a practical guide for cut point determination.
Copyright © 2012 Elsevier B.V. All rights reserved.

Mesh:

Year:  2013        PMID: 23305975     DOI: 10.1016/j.jim.2012.12.008

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  6 in total

1.  Recommendations for Systematic Statistical Computation of Immunogenicity Cut Points.

Authors:  Viswanath Devanarayan; Wendell C Smith; Rocco L Brunelle; Mary E Seger; Kim Krug; Ronald R Bowsher
Journal:  AAPS J       Date:  2017-07-21       Impact factor: 4.009

2.  Mitigation of Pre-existing Antibodies to a Biotherapeutic in Non-clinical Species When Establishing Anti-drug Antibody Assay Cutpoint.

Authors:  Seema C Kumar; Jason A DelCarpini; Qiang Qu; Martin Kane; Boris Gorovits
Journal:  AAPS J       Date:  2016-11-21       Impact factor: 4.009

3.  Storage Conditions of Conjugated Reagents Can Impact Results of Immunogenicity Assays.

Authors:  Robert J Kubiak; Nancy Lee; Yuan Zhu; William R Franch; Sophia V Levitskaya; Surekha R Krishnan; Varghese Abraham; Peter F Akufongwe; Christopher J Larkin; Wendy I White
Journal:  J Immunol Res       Date:  2016-07-10       Impact factor: 4.818

4.  Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.

Authors:  Martin R Gaudinski; Emily E Coates; Katherine V Houser; Grace L Chen; Galina Yamshchikov; Jamie G Saunders; LaSonji A Holman; Ingelise Gordon; Sarah Plummer; Cynthia S Hendel; Michelle Conan-Cibotti; Margarita Gomez Lorenzo; Sandra Sitar; Kevin Carlton; Carolyn Laurencot; Robert T Bailer; Sandeep Narpala; Adrian B McDermott; Aryan M Namboodiri; Janardan P Pandey; Richard M Schwartz; Zonghui Hu; Richard A Koup; Edmund Capparelli; Barney S Graham; John R Mascola; Julie E Ledgerwood
Journal:  PLoS Med       Date:  2018-01-24       Impact factor: 11.069

5.  Serum Samples from Co-Infected and Domestic Cat Field Isolates Nonspecifically Bind FIV and Other Antigens in Enzyme-Linked Immunosorbent Assays.

Authors:  Alex Moskaluk; Mary Nehring; Sue VandeWoude
Journal:  Pathogens       Date:  2021-05-28

6.  Selective Binding of HSC70 and its Co-Chaperones to Structural Hotspots on CFTR.

Authors:  Imad Baaklini; Conrado de Campos Gonçalves; Gergely L Lukacs; Jason C Young
Journal:  Sci Rep       Date:  2020-03-06       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.